Kutsch, Nadine, Busch, Raymonde, Bahlo, Jasmin, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg ORCID: 0000-0002-8321-1342, Hess, Georg, von Gruenhagen, Ulrich, Wendtner, Clemens-Martin, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2017). FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 58 (2). S. 399 - 408. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kutsch, NadineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Busch, RaymondeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bahlo, JasminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, JiriUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hensel, ManfredUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hopfinger, GeorgUNSPECIFIEDorcid.org/0000-0002-8321-1342UNSPECIFIED
Hess, GeorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Gruenhagen, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wendtner, Clemens-MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fink, Anna MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, KirstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-242010
DOI: 10.1080/10428194.2016.1190966
Journal or Publication Title: Leuk. Lymphoma
Volume: 58
Number: 2
Page Range: S. 399 - 408
Date: 2017
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
EUROPEAN-ORGANIZATION; EORTC QLQ-C30; FREE SURVIVAL; CYCLOPHOSPHAMIDE; FLUDARABINE; QUESTIONNAIRE; RITUXIMAB; IMPACTMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/24201

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item